public://oembed_thumbnails/vZpoosqN6f5mV_L83kF6OrLWx-RlCPzNq4knnCI0SBE.jpg


June 22 at 6:00 am PDT / 9:00 am EDT

Around the world, numbers of type 1 diabetes (T1D) cases are rising. It's expected that by 2050, 5 million people in the United States alone will have been diagnosed. T1D can be diagnosed at any age, even in infancy, and is a treatable—but not curable—condition. With patients and their families encumbered by financial burdens, lifestyle changes, and psychosocial repercussions, the development of new therapies for T1D is imperative This is a pivotal time for T1D research, with new treatment technologies, such as the artificial pancreas, and promising discoveries in the prevention and cure space. This discussion will highlight the perspectives of various stakeholders who are working together to help people affected by T1D. Panelists will share their enthusiasm over new treatments and innovations, and will assess the resources needed to overcome current challenges in T1D investigation.


Welcoming Remarks

Kathryn (Katie) O'Reilly
Executive Director, Business and Program Development, Milken Institute
 

Moderator

Kelly Close
Founder and Chair, The diaTribe Foundation; President, Close Concerns
 

Speakers

Aaron Kowalski
CEO, JDRF International

Shideh Majidi
Assistant Professor, Pediatric Endocrinology, Barbara Davis Center for Diabetes

Felicia Pagliuca
Vice President and Disease Area Executive, Type 1 Diabetes, Vertex Pharmaceuticals

David Pearce
President of Innovation, Research and World Clinic, Sanford Research
 

Materials

Type 1 Diabetes Autoantibody Screening: A Roadmap for Pediatric Policy Implementation